ArticleDiscover oncology2026
CircLRIG1 inhibits the malignant phenotypes of colorectal cancer cells by inactivating the NF-κB signaling through interaction with FUS.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCircLRIG1 has been demonstrated to inhibit the progression of bladder cancer. However, the expression profile and function of circLRIG1 in colorectal cancer (CRC), the third most prevalent malignancy globally, remain to be explored.
methodsCircLRIG1 (circBase ID: hsa_circ_0003266) expression was first analyzed in the GSE142837 dataset and subsequently validated in CRC tissues and cell lines. HT-29 and LoVo cells were subjected to gain- and loss-of-function manipulations to delineate the impact of circLRIG1 on the proliferation, migration, and apoptosis of CRC cells. RNA-binding proteins (RBPs) interacting with circLRIG1 were predicted by bioinformatic analysis, and verified by RNA pull-down and RNA immunoprecipitation assays, subcellular fractionation, and rescue experiments. Western blot and immunofluorescence were employed to assess the effects of circLRIG1 and FUS on total and phosphorylated p65 levels as well as p65 nuclear translocation. The NF-κB inhibitor PDTC was applied to circLRIG1-silenced CRC cells, and the malignant phenotypes were assessed. Finally, the tumor-suppressive capacity of circLRIG1 was evaluated in mouse subcutaneous xenograft models.
resultsCircLRIG1 was lowly expressed in CRC tissues and cell lines. Its expression was inversely correlated with advanced pathological features of CRC patients. Overexpression of circLRIG1 inhibited CRC cell proliferation, migration, and induced apoptosis. Conversely, silencing of circLRIG1 revealed the opposite effects. Mechanistically, circLRIG1 binds to FUS and inhibits its nuclear export, leading to the inactivation of NF-κB signaling. In vivo, circLRIG1 upregulation suppressed tumor growth, reduced the levels of Ki-67 and MMP9, and inhibited p65 phosphorylation.
conclusionsCircLRIG1 inhibits CRC progression through interaction with FUS to inactivate the NF-κB pathway. This may offer a promising therapeutic strategy for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.